Aspetti clinici e nuove opportunità terapeutiche
|
|
|
- Clare Jackson
- 5 years ago
- Views:
Transcription
1 Aspetti clinici e nuove opportunità terapeutiche Fabio Tumietto Programma Epidemiologia e Controllo del Rischio Infettivo Correlato alle Organizzazioni Sanitarie Clinica Malattie Infettive - Bologna
2 The generally accepted definition of complicated UTI includes infection in the presence of factors that predispose to persistent or relapsing infection, such as - foreign bodies (e.g., calculi, indwelling catheters or other drainage devices); - obstruction; - immunosuppression; - renal failure; - renal transplantation; - urinary retention from neurologic disease - infection in men, - pregnant women, - children, - patients who are hospitalized or in health care associated settings may be considered complicated
3 International Study of the Prevalence and Outcomes of Infection in Intensive Care Units JL Vincent et al; JAMA 2009, 302: Point prevalence study International ICUs (n=1,265) Population: 13,796 patients; 51% infected Cohort Mean SOFA score: % medical, 72% surgery/trauma 56% on mechanical ventilation
4 International Study of the Prevalence and Outcomes of Infection in Intensive Care Units JL Vincent et al; JAMA 2009, 302: No. (%) a Site of Infection All North America Western Europe Eastern Europe Central/ South America Oceania Africa Asia No. (%) Respiratory tract Abdominal Blood stream 7087 (51.4) 607 (48.4) 3683 (49) 426 (56.4) 1290 (60.3) 285 (48.2) 89 (46.1) 707 (52.6) 4503 (63.5) 345 (56.8) 2332 (63.3) 305 (71.6) b 851 (66) 165 (57.9) 41 (46.1) b 464 (6 5.6) 1392 (19.6) 1071 (15.1) 101 (16.6) 778 (21.1) 93 (21.8) 228 (17.7) b 50 (17.5) 16 (18) 126 (17.8) 157 (25.9) 546 (14.8) 53 (12.4) 139 (10.8) b 49 (17.2) 16 (18) 111 (15.7) Renal/urinary tract 1011 (14.3) 135 (22.2) 411 (11.2) 84 (19.7) b 222 (17.2) b 33 (11.6) 15 (16.9) 111 (15.7) b Skin 467 (6.6) 26 ( 4.3) 242 (6.6) 37 (8.7) 73 (5.7) 30 (10.5) 8 (9.0) 51 (7.2) Catheterrelated 332 (4.7) 16 (2.6) 171 (4.6) 21 (4.9) 73 (5.7) 15 (5.3) 4 (4.5) 32 (4.5) CNS 208 (2.9) 14 ( 2.3) 100 (2.7) 20 (4.7) 40 (3.1) 11 (3.9) 4 (4.5) 19 (2.7) Others 540 (7.6) 62 (10.2) 289 (7.8) 31 (7.3) 87 (6.7) 22 (7.7) 14 (15.7) b 35 (5.0) b
5
6 Evolution of Gram-neg pathogens has caused widespread drug resistance Susceptible gram-negative pathogens 1960s Ampicillin Resistant Escherichia coli TEM SHV serine -lactamases Resistant E. coli, Pseudomonas aeruginosa and Klebsiella spp. AcrAB bla SHV bla TEM AmpC-type -lactamases 1980s Cephalosporins Fluoroquinolones (1990s) Resistant E. coli, P. aeruginosa, Klebsiella spp., Enterobacter spp. CTX-M-15 VIM IMP NDM-1 Porin defects Metallo -lactamases 1. Hawkey. Antimicrob Chemother. 2008;62:i Hawkey and Jones. J Antimicrob Chemother. 2009;64:i Bush. Antimicrob. Agents Chemother. 2010;54: Livermore. Clin Infect Dis. 2002;34: Olivares et al. Front Microbiol. 2013;4: s Carbapenems
7 Carbapenem resistance (%) Carbapenem consumption (DDDs) Correlation between carbapenem consuption and P.aeruginosa resistance Lepper PM, et al. Antimicrob Agents Chemother. 2002;46:
8 25 Feb 2017
9
10 Resistance in Gram- pathogens: Challenges and opportunities Resistance = morbidity & mortality Resistant Gram- in community & hospital settings Enhanced infection control practices required Different mechanisms of resistance cause different relative change in MIC from wild type Porin / Efflux / Target site modest in MICs Enzyme mediated in MICs PD optimize dosing can overcome modest MIC increases Enzyme mediated MICs require different Tx strategies
11 Optimize antimicrobial exposures Anticipate impact of host on exposure Increased clearance Increased volume of distribution Determine MICs of target pathogen(s) Optimize PD using: Highest tolerated doses Altered infusion techniques (i.e., Prolonged or Continuous infusion) Combination therapy Consider availability of new potent agents Most expensive antibiotic is the one that doesn t work FAILURE LOS & Cost of Care
12 Gram- negative resistance: Four major areas of need Resistant Gramnegative Phenotype ESBL-producing Enterobacteriaceae MDR P. aeruginosa Carbapenem-resistant Enterobacteriaceae (e.g. KPC) Metallo-β-lactamaseproducers CDC Threat Level Serious Serious Urgent N/A Estimated Cases & Attributable Deaths in US per Year 26,000 cases 1,700 deaths 6,000 cases 400 deaths 9,300 cases 610 deaths Very rare CDC, Antibiotic Resistance Threats in the US, 2013.
13 Ceftolozane/ Tazobactam Superior antipseudomonal activity compared to ceftazidime Active against most ESBL and Amp C-producing organisms Covers most ESBL-producing E. coli, Klebsiella pneumoniae, and other Enterobacteriaceae Covers most AmpC producers Does not have activity against KPC or MBLs
14 In 2013, the Centers for Disease Control and Prevention identified CRE as nightmare bacteria and an immediate public health threat that requires urgent and aggressive action
15 The virtues of Avibactam Avibactam inactivates most important β-lactamases except metallo types and Acinetobacter OXA carbapenemases Even metalloenzymes can be overcome by combining avibactam with aztreonam, which is stable to metallo- β-lactamases, but vulnerable to the ESBLs and AmpC enzymes that often accompany them
16 Activity of CAZ / AVI Activity against ESBLs and some carbapenem resistant Enterobacteriaceae Most KPC producers are susceptibile Strains which are carbapenem resistant due to porin loss plus production of an ESBL or AmpC are susceptible
17 CEFTOLOZANE/TAZOBACTAM is indicated for the treatment of the following infections in adults: Complicated intra-abdominal infections; Acute pyelonephritis; Complicated urinary tract infections CEFTAZIDIME/AVIBACTAM is indicated for the treatment of the following infections in adults: Complicated intra-abdominal infection (ciai) Complicated urinary tract infection (cuti), including pyelonephritis Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP). Ceftazidime/avibactam is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
18 MA a ME SERVONO ANTIBIOTICI per INFEZIONI delle VIE URINARIE, INFEZIONI di CUTE e TESSUTI MOLLI, INFEZIONI ADDOMINALI oppure ANTIBIOTICI per MDR???? problema regolatorio/registrativo
19 TERAPIA ANTI-INFETTIVA - CRITICITA Scarsa cultura specifica nel mondo medico tutti prescrivono tutto molti usano male Nessun coinvolgimento degli infermieri nella responsabilità prescrittiva Poca aderenza al concetto di gradualità della prescrizione il massimo ai pazienti gravi il minimo ai pazienti stabili Utilizzo sub-ottimale delle risorse della microbiologia Scarsa cultura rispetto alla necessità di approccio multidisciplinare in specifici contesti
20 Current evidence and expert opinion support the following elements as effective to support the prudent use of antimicrobials in healthcare: 1. International organisations and agencies 2. National, regional and local governments 3. Healthcare facilities (resources, systems and processes) 4. Clinical microbiologists 5. Infectious disease specialists 6. Prescribers 7. Pharmacists 8. Nurses 9. Infection control practitioners 10. Public/patients 11. Professional associations and scientific societies 12. Research funders 13. Pharmaceutical industry 14. Diagnostics industry European Centre for Disease Prevention and Control, 2017
21 Prevalence of antimicrobial use (percentage of patients receiving at least one antimicrobial agent) in European hospitals, by country, ECDC PPS SURVEILLANCE REPORT Healthcare-associated infections and antimicrobial use,
22 AMS WHERE???? Tasso di consumo di antibiotici in Emilia-Romagna, espresso in DDD/1.000 abitanti-die (AFT e AFO )
23
24 80 anni di successi? 80 anni di sconfitte?
25 Antimicrobial Resistance HD Marston et al; JAMA 2016, 316: Time From Antibiotic Approval or Introduction to Detection of Resistance in Clinical Samples
26 European Centre for Disease Prevention and Control. Last-line antibiotics are failing: options to address this urgent threat to patients and healthcare systems. Stockholm: ECDC; 2016
27 LA CRISI DEGLI ANTIBIOTICI: QUALI RISPOSTE Nuovi farmaci Terapie alternative Strategie di prevenzione Anti-Microbial Stewardship AMS: visione di sistema della terapia antimicrobica. Uscire dall individualismo terapeutico per passare ad una filosofia di utilizzo ecologico degli antimicrobici
28
29
30
31
32
33 A Program to Prevent Catheter-Associated Urinary Tract Infection in Acute Care S Saint et al, NEJM 2016; 374:2111-9
34
35
36
37
38
39
40 Aspetti clinici e nuove opportunità terapeutiche Fabio Tumietto Programma Epidemiologia e Controllo del Rischio Infettivo Correlato alle Organizzazioni Sanitarie Clinica Malattie Infettive - Bologna
Fighting MDR Pathogens in the ICU
Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial
Samantha Trumm, Pharm.D. PGY-1 Resident Avera McKennan Hospital and University Center
Samantha Trumm, Pharm.D. PGY-1 Resident Avera McKennan Hospital and University Center I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in
Intrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
Multi-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL
Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital
Breaking the Ring. β-lactamases and the Great Arms Race. Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester
Breaking the Ring β-lactamases and the Great Arms Race Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester 2015 MFMER slide-1 Disclosures I have no relevant financial relationships
ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens
ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens Ruben Tommasi, PhD Chief Scientific Officer ECCMID 2017 April 24, 2017 Vienna, Austria
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)
Multidrug Resistant Organisms (MDROs) Kasturi Shrestha, M.D. 05/11/2018 Objectives Define a multi-drug resistant organism (MDRO) Identify most challenging MDROs in healthcare Identify reasons for health
Antimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
Rise of Resistance: From MRSA to CRE
Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance
Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
RETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR
Original article RETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR R.Sujatha 1,Nidhi Pal 2, Deepak S 3 1. Professor & Head, Department
UK guidelines for GNB infections
UK guidelines for GNB infections PROFESSOR PETER M. HAWKEY Institute of Microbiology and Infection (IMI), University of Birmingham, Birmingham, B14 2TT, UK Public Health England (PHE), Public Health Laboratory
DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA
DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA The good old days The dread (of) infections that used to rage through the whole communities is muted Their retreat
ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae
ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;
Carbapenemase-producing Enterobacteriaceae (CRE) T H E L A T E S T I N T H E G R O W I N G L I S T O F S U P E R B U G S
Carbapenemase-producing Enterobacteriaceae (CRE) T H E L A T E S T I N T H E G R O W I N G L I S T O F S U P E R B U G S CRE Enterobacteriaceae (Gram Negative Bacilli) Citrobacter species Escherichia coli***
Epidemiology and Burden of Antimicrobial-Resistant P. aeruginosa Infections
Epidemiology and Burden of Antimicrobial-Resistant P. aeruginosa Infections Keith S. Kaye, MD, MPH Professor of Medicine Division of Infectious Diseases Department of Internal Medicine University of Michigan
Antibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011
Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond
Witchcraft for Gram negatives
Witchcraft for Gram negatives Dr Subramanian S MD DNB MNAMS AB (Medicine, Infect Dis) Infectious Diseases Consultant Global Health City, Chennai www.asksubra.com Drug resistance follows the drug like a
Addressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broadspectrum
Addressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broadspectrum activity against Class A, C and D enzymes Alita Miller, PhD
Nosocomial Infections: What Are the Unmet Needs
Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com
MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
ESCMID Online Lecture Library. by author
Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA
New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs
New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs Patrick R. Murray, PhD Senior Director, WW Scientific Affairs 2017 BD. BD, the BD Logo and all other trademarks
April 25, 2018 Edited by: Gregory K. Perry, PharmD, BCPS-AQID
VOLUME FOUR; ISSUE 4 April 25, 2018 Edited by: Gregory K. Perry, PharmD, BCPS-AQID InPHARMation Pharmacy and Therapeutics Committee Update April 25 th, 2018 Meeting The Pharmacy and Therapeutics Committee
What s next in the antibiotic pipeline?
What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics
Comparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria
Comparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria Juhee Ahn Department of Medical Biomaterials Engineering Kangwon National University October 23, 27 Antibiotic Development
9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS
Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS 1 2 Untoward Effects of Antibiotics Antibiotic resistance Adverse drug events (ADEs) Hypersensitivity/allergy Drug side effects
FIS Resistance Surveillance: The UK Landscape. Alasdair MacGowan Chair BSAC Working Party on Antimicrobial Resistance Surveillance
FIS 2013 Resistance Surveillance: The UK Landscape Alasdair MacGowan Chair BSAC Working Party on Antimicrobial Resistance Surveillance A statement of the obvious Good quality surveillance data on resistant
Infection Control of Emerging Diseases
2016 EPS Training Event Martin E. Evans, MD Director, VHA MDRO Program National Infectious Diseases Service Lexington, KY & Cincinnati, OH Infection Control of Emerging Diseases 2016 EPS Training Event
2015 Antimicrobial Susceptibility Report
Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf
03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline
Infection Prevention and Control A Foundation Course 2014 What is healthcare-associated infection (HCAI), antimicrobial resistance (AMR) and multi-drug resistant organisms (MDROs)? Why we should be worried?
Mono- versus Bitherapy for Management of HAP/VAP in the ICU
Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,
The role of new antibiotics in the treatment of severe infections: Safety and efficacy features
The role of new antibiotics in the treatment of severe infections Safety and efficacy features Christian Eckmann Hannover, Germany The role of new antibiotics in the treatment of severe infections: Safety
Updates on the Management of Hospital Acquired Infections and Resistant Organisms
Updates on the Management of Hospital Acquired Infections and Resistant Organisms Conflict of Interest I, Kaitlin McGinn, have no actual or potential conflict of interest in relation to this program. Kaitlin
Updates on the Management of Hospital Acquired Infections and Resistant Organisms
Updates on the Management of Hospital Acquired Infections and Resistant Organisms Kaitlin McGinn, PharmD Assistant Clinical Professor, Critical Care Auburn University, Harrison School of Pharmacy November
CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)
CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.
PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE
PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse
Mechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
Presenter: Ombeva Malande. Red Cross Children's Hospital Paed ID /University of Cape Town Friday 6 November 2015: Session:- Paediatric ID Update
Emergence of invasive Carbapenem Resistant Enterobacteriaceae CRE infection at RCWMCH Ombeva Oliver Malande, Annerie du Plessis, Colleen Bamford, Brian Eley Presenter: Ombeva Malande Red Cross Children's
OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
A snapshot of polymyxin use around the world South America
A snapshot of polymyxin use around the world South America Alexandre P. Zavascki Infectious Diseases Service, Hospital de Clínicas de Porto Alegre Medical School, Federal University of Rio Grande do Sul
Summary of the latest data on antibiotic resistance in the European Union
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
Prevention, Management, and Reporting of Carbapenem-Resistant Enterobacteriaceae
Prevention, Management, and Reporting of Carbapenem-Resistant Enterobacteriaceae Dawn Terashita MD, MPH Acute Communicable Disease Control Los Angeles County Department of Public Health September 28, 2017
10/9/2012. Unprecedented success of antibiotics in 1960s. Infectious diseases are #1 cause of mortality worldwide
I have no conflicts of interest in relation to this program Whitney Jones, PharmD Antimicrobial Stewardship Pharmacist Vanderbilt University Medical Center October 25, 2012 Understand the epidemiology
Combating Drug-Resistant Infections Globally. Company Presentation
Combating Drug-Resistant Infections Globally Company Presentation Forward-Looking Statements and Other Important Cautions Any statement in this presentation about our future expectations, plans and prospects,
Combating Drug-Resistant Infections Globally. Company Presentation
Combating Drug-Resistant Infections Globally Company Presentation Forward-Looking Statements and Other Important Cautions Any statement in this presentation about our future expectations, plans and prospects,
Antimicrobial Stewardship:
Antimicrobial Stewardship: Inpatient and Outpatient Elements Angela Perhac, PharmD afperhac@carilionclinic.org Disclosure I have no relevant finances to disclose. Objectives Review the core elements of
Introduction to antimicrobial resistance
Introduction to antimicrobial resistance Philip Howard Consultant Antimicrobial Pharmacist HCAI and AMR Project Lead 4 th March 2015 What is antimicrobial resistance? Antibacterials either kill or stop
Governance e sostenibilità nell antibioticoterapia. Anna Maria Cattelan UOC Malattie Infettive Azienda Ospedaliera Universitaria Padova
Governance e sostenibilità nell antibioticoterapia Anna Maria Cattelan UOC Malattie Infettive Azienda Ospedaliera Universitaria Padova 16 years ago, in an editorial in the first issue of The Lancet Infectious
1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection
Surveillance, Outbreaks, and Reportable Diseases, Oh My! Assisted Living Facility, Nursing Home and Surveyor Infection Prevention Training February 2015 A.C. Burke, MA, CIC Health Care-Associated Infection
RESISTANT PATHOGENS. John E. Mazuski, MD, PhD Professor of Surgery
RESISTANT PATHOGENS John E. Mazuski, MD, PhD Professor of Surgery Disclosures Contracted Research: AstraZeneca, Bayer, Merck. Advisory Boards/Consultant: Allergan (Actavis, Forest Laboratories), AstraZeneca,
Bad Bugs. Pharmacist Learning Objectives. Antimicrobial Resistance. Patient Case. Pharmacy Technician Learning Objectives 4/8/2016
Pharmacist Learning Objectives Antimicrobial Resistance Julie Giddens Pharm D, BCPS Infectious Disease Clinical Pharmacist OSF Saint Francis Medical Center Peoria, IL The speaker has no conflicts to disclose
Learning Points. Raymond Blum, M.D. Antimicrobial resistance among gram-negative pathogens is increasing
Raymond Blum, M.D. Learning Points Antimicrobial resistance among gram-negative pathogens is increasing Infection with antimicrobial-resistant pathogens is associated with increased mortality, length of
Hospital Acquired Infections in the Era of Antimicrobial Resistance
Hospital Acquired Infections in the Era of Antimicrobial Resistance Datuk Dr Christopher KC Lee Infectious Diseases Unit Department of Medicine Sungai Buloh Hospital Patient Story 23 Year old female admitted
EARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
Appropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities
REVIEW Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities Fiona Walsh Department of Clinical Microbiology, Trinity College Dublin, Dublin, Ireland
Report on the APUA Educational Symposium: "Facing the Next Pandemic of Pan-resistant Gram-negative Bacilli"
Preserving the Power of Antibiotics Report on the APUA Educational Symposium: "Facing the Next Pandemic of Pan-resistant Gram-negative Bacilli" Held on Thursday, September 30, 2004 in Boston, MA Preceding
Outline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
Workplan on Antibiotic Usage Management
IMPACT Forum: Antibiotic Guideline in Perspective Workplan on Antibiotic Usage Management Dr. Raymond Yung Consultant Microbiologist PYNEH 20 April 2002 May 2002 Dr. Raymond Yung 1 Objective 1. Heighten
Prevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
Dr Kamini Walia Indian Council of Medical Research
Dr Kamini Walia Indian Council of Medical Research The apex body in India for the formulation, coordination and promotion of biomedical research under Department of Health Research, Ministry of Health
Carbapenemase-Producing Enterobacteriaceae (CPE)
Carbapenemase-Producing Enterobacteriaceae (CPE) September 21, 2017 Maryam Khan Peel Public Health Madeleine Ashcroft Public Health Ontario Objectives Differentiate the acronyms related to CPE (CPE,CPO,CRE,CRO)
on April 8, 2018 by guest
AAC Accepted Manuscript Posted Online 9 January 2017 Antimicrob. Agents Chemother. doi:10.1128/aac.02252-16 Copyright 2017 American Society for Microbiology. All Rights Reserved. 1 2 3 4 Antimicrobial
β-lactams resistance among Enterobacteriaceae in Morocco 1 st ICREID Addis Ababa March 2018
β-lactams resistance among Enterobacteriaceae in Morocco 1 st ICREID Addis Ababa 12-14 March 2018 Antibiotic resistance center Institut Pasteur du Maroc Enterobacteriaceae (E. coli, Salmonella, ) S. aureus
Dr. Shaiful Azam Sazzad. MD Student (Thesis Part) Critical Care Medicine Dhaka Medical College
Dr. Shaiful Azam Sazzad MD Student (Thesis Part) Critical Care Medicine Dhaka Medical College INTRODUCTION ICU acquired infection account for substantial morbidity, mortality and expense. Infection and
Prevalence of Extended-spectrum β-lactamase Producing Enterobacteriaceae Strains in Latvia
Prevalence of Extended-spectrum β-lactamase Producing Enterobacteriaceae Strains in Latvia Ruta Paberza 1, Solvita Selderiņa 1, Sandra Leja 1, Jelena Storoženko 1, Lilija Lužbinska 1, Aija Žileviča 2*
Antibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship
Antibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship J. Hudson Garrett Jr., PhD, MSN, MPH, FNP-BC, PLNC, CDONA, IP-BC, GDCN, CDP, CADDCT, CALN, VA-BC, AS-BC,
Preventing and Responding to Antibiotic Resistant Infections in New Hampshire
Preventing and Responding to Antibiotic Resistant Infections in New Hampshire Benjamin P. Chan, MD, MPH NH Dept. of Health & Human Services Division of Public Health Services May 23, 2017 To bring a greater
1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient
1 Chapter 79, Self-Assessment Questions 1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient with normal renal function is: A. Trimethoprim-sulfamethoxazole B. Cefuroxime
The Rise of Antibiotic Resistance: Is It Too Late?
The Rise of Antibiotic Resistance: Is It Too Late? Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine None DISCLOSURES THE PROBLEM Antibiotic resistance is one of the
Antibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
ESBL- and carbapenemase-producing microorganisms; state of the art. Laurent POIREL
ESBL- and carbapenemase-producing microorganisms; state of the art Laurent POIREL Medical and Molecular Microbiology Unit Dept of Medicine University of Fribourg Switzerland INSERM U914 «Emerging Resistance
Antibiotics 201: Gramnegatives
Antibiotics 201: Gramnegatives B. Joseph Guglielmo, Pharm.D. Professor and Dean School of Pharmacy University of California San Francisco Disclosures No potential conflicts of interest. 1 A 77 year old
Infection Prevention and Control Policy
Infection Prevention and Control Policy Control of Multi-Drug-Resistant Gram-Negative Bacilli N.B. Staff should be discouraged from printing this document. This is to avoid the risk of out of date printed
Antimicrobial Resistance: A Growing Concern for Healthcare Security and Resilience
Antimicrobial Resistance: A Growing Concern for Healthcare Security and Resilience Neil Woodford HPA AMRHAI - Colindale Resistance is entirely natural...and is ancient Permafrost samples Late Pleistocene
Dissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters
Dissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters Jon Otter, PhD Centre for Clinical Infection and Diagnostics Research (CIDR), King's College London & Guy's and St. Thomas'
Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance
Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance Robert C Welliver Sr, MD Hobbs-Recknagel Endowed Chair in Pediatrics Chief, Pediatric infectious Diseases Children s Hospital
9.5 Antimicrobial Resistance
9.5 Antimicrobial Resistance Key Points In 215, there was a slight reduction in coverage of the Irish population by EARS-Net versus 214, from 1% to 97% There were 2,697 reports of invasive Escherichia
Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing
Infect Dis Ther (2015) 4:513 518 DOI 10.1007/s40121-015-0094-6 BRIEF REPORT Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate
Resistant Gram-negative Bacteria
Introduction Antibiotic-resistant bacteria aren t new. But gram-negative bacteria, like Enterobacteriaceae, are becoming more resistant to our last-line antibiotics. Some people are calling these bacteria
Antimicrobial Resistance Strains
Antimicrobial Resistance Strains Microbiologics offers a wide range of strains with characterized antimicrobial resistance mechanisms including: Extended-Spectrum β-lactamases (ESBLs) Carbapenamases Vancomycin-Resistant
Rise of the Superbugs: the end of antibiotics? Peter Lambert Life and Health Sciences Aston University
Rise of the Superbugs: the end of antibiotics? Peter Lambert Life and Health Sciences Aston University Willard Wigan Microbiologists grow bacteria on plates Each colony is formed from a single cell Colonies
MDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta
MDR Acinetobacter baumannii Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta 1 The Armageddon recipe Transmissible organism with prolonged environmental
Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version
Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED 2018 Printed copies must not be considered the definitive version DOCUMENT CONTROL POLICY NO. IC-122 Policy Group Infection Control
The impact of antimicrobial resistance on enteric infections in Vietnam Dr Stephen Baker
The impact of antimicrobial resistance on enteric infections in Vietnam Dr Stephen Baker sbaker@oucru.org Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam Outline The impact of antimicrobial
Mili Rani Saha and Sanya Tahmina Jhora. Department of Microbiology, Sir Salimullah Medical College, Mitford, Dhaka, Bangladesh
Detection of extended spectrum beta-lactamase producing Gram-negative organisms: hospital prevalence and comparison of double disc synergy and E-test methods Mili Rani Saha and Sanya Tahmina Jhora Original
Preserving bacterial susceptibility Implementing Antimicrobial Stewardship Programs Debra A. Goff, Pharm.D., FCCP
Preserving bacterial susceptibility Implementing Antimicrobial Stewardship Programs Debra A. Goff, Pharm.D., FCCP Clinical Associate Professor Infectious Diseases Specialist The Ohio State University Medical
Surveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at Chiang Mai University Hospital,
Original Article Vol. 28 No. 1 Surveillance of Antimicrobial Resistance:- Chaiwarith R, et al. 3 Surveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
Imagine. Multi-Drug Resistant Superbugs- What s the Big Deal? A World. Without Antibiotics. Where Simple Infections can be Life Threatening
Multi-Drug Resistant Superbugs- What s the Big Deal? Toni Biasi, RN MSN MPH CIC Infection Prevention Indiana University Health Imagine A World Without Antibiotics A World Where Simple Infections can be
Antibiotico resistenza in clinica
Dr Bruno Viaggi Dipartimento di Anestesia SOD NeuroAnestesia e Rianimazione CTO AOUC Antibiotico resistenza in clinica Dichiarazione su potenziali conflitti di interesse Consulenze, partecipazione advisory
Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16
Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America
Cost high. acceptable. worst. best. acceptable. Cost low
Key words I Effect low worst acceptable Cost high Cost low acceptable best Effect high Fig. 1. Cost-Effectiveness. The best case is low cost and high efficacy. The acceptable cases are low cost and efficacy
Prevention and control of antimicrobial resistance in healthcare settings: raising awareness about best practices
Prevention and control of antimicrobial resistance in healthcare settings: raising awareness about best practices Dominique L. Monnet, on behalf of ECDC Antimicrobial Resistance and Healthcare-Associated
ADC 2016 Report on Bacterial Resistance in Cultures from SEHOS and General Practitioners in Curaçao
ADC 216 Report on Bacterial Resistance in Cultures from SEHOS and General Practitioners in Curaçao Willemstad, November 217 Authors: Radjin Steingrover clinical microbiologist, head dpt. Microbiology ADC
Sepsis is the most common cause of death in
ADDRESSING ANTIMICROBIAL RESISTANCE IN THE INTENSIVE CARE UNIT * John P. Quinn, MD ABSTRACT Two of the more common strategies for optimizing antimicrobial therapy in the intensive care unit (ICU) are antibiotic